Ibrutinib
janssen,abbvie
['oval', 'rova', 'sequence', 'mantle,(-dismantle)']
right after this trial was launched in 2013, ibrutinib got mantle cell approval. sequence was then the only question this trial continued to enroll for 1 more year, measuring a bad endpoint with bad post protocol care and now it is pretty useless for docs &amp; pts #asco2022 
Medicine Oncology Science Policy
Academic Pubs @vkprasadlab
Podcast @plenary_session
Clips on YouTube ??
Books EMR & Malignant
Prof @ucsf_epibiostat
Views mine